BluePrint resource: PCSK9 inhibitor therapies in ACS
BluePrint resource: PCSK9 inhibitor therapies in ACS
Prof. Dr. Anna Franzone, Prof. Dr. Jeanine Roeters van Lennep, Prof. Dr. Uwe Zeymer, Dr. Flavien Vincent, Prof. Dr. Zuzana Motovska
Prof. Dr. Anna Franzone
Cardiologist
Federico II University of Naples
Italy
Prof. Dr. Jeanine Roeters van Lennep
Internist, Vascular Medicine
Erasmus Medical Center
Netherlands
Prof. Dr. Uwe Zeymer
Cardiologist
Heart Center Ludwigshafen
Germany
Dr. Flavien Vincent
Cardiologist
Lille University Hospital
France
Prof. Dr. Zuzana Motovska
Cardiologist
Charles University
Czech Republic
Prof. Dr. Anna Franzone
Cardiologist
Federico II University of Naples
Italy
Dr. Franzone is an Assistant Professor of Cardiology at Federico II University of Naples. Her education in the field started before graduation through experiences in molecular basic research: she has planned and performed experiments in animal models of myocardial infarction and pathological cardiac hypertrophy. She also studied the molecular basis of atherosclerosis and its related translational aspects in clinical practice. The results of these initial investigations were published in high impact journals in the field of cardiovascular medicine. During the residency at the School of Cardiology of Federico II University of Naples, Dr. Franzone started her practice in interventional cardiology and focused her research interest in the field of coronary and structural heart interventions. Since 2014, she attended the PhD program in Clinical and Experimental Medicine and completed a clinical fellowship at Bern University Hospital where she had the opportunity to further advance the scientific knowledge in the field of interventional cardiology and to publish several papers on the topic. Her research focus converged to the percutaneous treatment of coronary and aortic valve disease. In addition, she showed interpersonal skills that allowed her to cultivate a strong team environment and join international collaborations. Dr. Franzone is an active member of the main cardiological international societies and boards.
Prof. Dr. Anna Franzone has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Dr. Jeanine Roeters van Lennep
Internist, Vascular Medicine
Erasmus Medical Center
Netherlands
Jeanine Roeters van Lennep has been working as internist specialized in vascular medicine at the Erasmus Medical Center, Rotterdam, the Netherlands since 2010. She is associate professor and head of the vascular medicine clinic specialized in hereditary dyslipidemia. She combines this research interest with gender-specific medicine. As such, her scientific research is dedicated to cardiovascular prevention, specifically diagnosis and treatment of Familial Hypercholesterolemia and sex-specific cardiovascular risk factors such as pre-eclampsia for which she obtained grants of e.g. the Dutch Heart Foundation and the Dutch Research Council. She is very eager to share her enthusiasm on sex- and gender-specific medicine by organizing educational activities such as the 3-day Gender&Health Course and mentoring junior doctors and researchers. Jeanine has broad leadership experience as board member of various scientific societies. Currently she is chair of the Dutch Society of Vascular Medicine, member of the executive committee of the European Atherosclerosis Society and board member of the Dutch Society of Gender&Health. Moreover she has been chair of the first Dutch Guideline on Dyslipidemia.
Prof. Dr. Jeanine Roeters van Lennep has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Dr. Uwe Zeymer
Cardiologist
Heart Center Ludwigshafen
Germany
Prof. Dr. Uwe Zeymer is Head of Interventional Cardiology at the Heart Center Ludwigshafen, Department of Cardiology, Germany. He is Vice-Director of the Institut für Herzinfarktforschung Ludwigshafen. He has been board certified in internal medicine, cardiology, interventional cardiology and intensive care medicine. After his graduation from Medical School at the Universities of Munich and Marburg in 1985, Dr Zeymer gained experience as a resident, fellow and attendee in the Department of Cardiology, Municipal Hospital, Kassel, and as a clinical research fellow in the Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, USA. He is full Professor of Medicine at the University of Göttingen. Dr. Zeymer is or has chaired or been a member of the Steering Committee numerous trials in patients with acute coronary syndromes, antithrombotic therapies and anticoagulants. In addition, he has been chair or member of the Steering committee of several international registries in interventional cardiology, treatment of hypertension, anticoagulation for atrial fibrillation and acute coronary syndromes. Dr. Zeymer has authored and co-authored over 450 scientific papers on cardiovascular disease in journals such as the New England Journal of Medicine, Lancet, JAMA, European Heart Journal, Circulation and Journal of the American College of Cardiology. Dr. Zeymer has been the Chair of the Scientific Committee of the Acute Cardiovascular Care Association of the ESC, the Chair of the Working Group of Thrombosis of the German Cardiac Society and the Chair of the Working for Quality Insurance and Registries of the German Cardiac Society. He was President of the annual Autumn Meeting of the German Cardiac Society 2013. He is currently chairing the ongoing STEMI-Registry of the EORP of the ESC.
Prof. Dr. Uwe Zeymer has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Dr. Flavien Vincent
Cardiologist
Lille University Hospital
France
Dr. Flavien Vincent is an attending interventional cardiologist affiliated with Lille University Hospital (Lille, France), and a researcher at the INSERM U1011 research unit. His research themes are the impact of arterial pulsatility on hemostasis disorders and the aortic and mitral mini-invasive transcatheter interventions. He received his medical degree and PhD from Lille University, France. He is currently a research fellow at the Cardiovascular Research Foundation in New York, NY, USA.
Dr. Flavien Vincent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Dr. Zuzana Motovska
Cardiologist
Charles University
Czech Republic
Present Position and Address Head of the Division of Acute Cardiology Deputy Head of Department for the Research Cardiology Department Cardiocenter Third Faculty of Medicine, Charles University University Hospital Kralovské Vinohrady Prague, Czech Republic Post Graduate Degrees Appointed as Professor of Internal Medicine at the Charles University, Prague, Czech Republic European Society of Cardiology Activities Councilor of the ESC Board 2018-2020 Member of Working group on Thrombosis Member of Acute Cardiovascular Care Association National coordinator of the ACS-STEMI Registry EORP Fellowships / Honours Fellow of European Society of Cardiology (since 2007) Award given by the Ministry of Education, Youth and Sports of Czech Republic for extraordinary results in research, experimental development and innovation – awarded in the year 2015 Major Research Interest Acute coronary syndromes Acute cardiac care Antithrombotic therapy Cardiovascular disease in women Cardiogenic shock Major Scientific Activities Principal investigator (design, leadership, coordination): Multicenter randomized PRAGUE 8 study Multicenter randomized PRAGUE 18 study Multicenter double-blind randomized DAPT-SCHOCK-AMI (PRAGUE 23) study (ongoing)
Prof. Dr. Zuzana Motovska has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 10 min | Sep 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Early (in-hospital) initiation of PCSK9 inhibitor therapy in patients with acute coronary syndrome may provide additional clinical benefit when used on top of statin treatment. This BluePrint describes current recommendations regarding low-density lipoprotein cholesterol targets in patients with ACS, the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rationale for its inhibition in ACS, and the expected clinical impact of PCSK9 inhibitors in the acute phase of ACS.
Development of this BluePrint was supported by an Independent Educational Grant from Amgen.
CORONARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Amgen.
Other programmes of interest
Other programmes developed by Prof. Dr. Jeanine Roeters van Lennep
Prof. Dr. Jeanine Roeters van Lennep
Internist, Vascular Medicine
Erasmus Medical Center
Netherlands